肾炎康复片联合环孢素A治疗难治性肾病综合征的临床研究
|
摘要
目的观察肾炎康复片联合环孢素软胶囊治疗难治性肾病综合征的临床疗效。方法选取2017年3月—2018年2月三二〇一医院收治的64例难治性肾病综合征患者作为研究对象,所有患者随机分为对照组和治疗组,每组各32例。对照组患者口服环孢素软胶囊,常用剂量为3 mg/(kg·d),分两次服用。治疗组在对照组治疗的基础上口服肾炎康复片,1片/次,3次/d。两组患者连续治疗6个月。观察两组患者的临床疗效,比较两组的血肌酐、血浆白蛋白、24 h尿蛋白水平和不良反应发生情况。结果治疗后,对照组和治疗组的总有效率分别为78.13%、93.75%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组血肌酐、血浆白蛋白、24 h尿蛋白均显著降低,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后治疗组血肌酐、血浆白蛋白、24 h尿蛋白明显低于对照组,两组比较差异有统计学意义(P<0.05)。治疗后,治疗组的不良反应发生率为18.7%,显著低于对照组的37.5%,两组比较差异具有统计学意义(P<0.05)。结论肾炎康复片联合环孢素软胶囊治疗难治性肾病综合征的疗效显著,可改善患者肾功能,且不良反应少,具有一定的临床推广应用价值。
Objective To observe the clinical efficacy of Shenyan Kangfu Tablets combined with Cyclosporin Soft Capsules in treatment of refractory nephrotic syndrome. Methods Patients(64 cases) with refractory nephrotic syndrome in San Er Ling Yi Hospital from March 2017 to February 2018 were randomly divided into control and treatment groups, and each group had 32 cases.Patients in the control group were po administered with Cyclosporin Soft Capsules, the commonly used dose was 3 mg/(kg·d), and took it twice. Patients in the treatment group were po administered with Shenyan Kangfu Tablets on the basis of the control group, 1 tablet/time, three times daily. Patients in two groups were treated for 6 months. After treatment, the clinical efficacy was evaluated, and the levels of serum creatinine, plasma albumin, and 24 h urine protein, and the adverse reaction in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 78.13% and 93.75%,respectively, and there were differences between two groups(P < 0.05). After treatment, the levels of serum creatinine, plasma albumin, and 24 h urine protein in two groups were significantly decreased, and there were differences in the same group(P < 0.05).After treatment, the levels of serum creatinine, plasma albumin, and 24 h urine protein in the treatment group were lower than those in the control group, and there were differences between two groups(P < 0.05). After treatment, the incidence of adverse reactions in the treatment group was 18.7%, which was significantly lower than 37.5% in the control group, with significant difference between two groups(P < 0.05). Conclusion Shenyan Kangfu Tablets combined with Cyclosporin Soft Capsules has significant efficacy in treatment of refractory nephrotic syndrome, can improve the renal function with less adverse reactions, which has a certain clinical application value.
Objective To observe the clinical efficacy of Shenyan Kangfu Tablets combined with Cyclosporin Soft Capsules in treatment of refractory nephrotic syndrome. Methods Patients(64 cases) with refractory nephrotic syndrome in San Er Ling Yi Hospital from March 2017 to February 2018 were randomly divided into control and treatment groups, and each group had 32 cases.Patients in the control group were po administered with Cyclosporin Soft Capsules, the commonly used dose was 3 mg/(kg·d), and took it twice. Patients in the treatment group were po administered with Shenyan Kangfu Tablets on the basis of the control group, 1 tablet/time, three times daily. Patients in two groups were treated for 6 months. After treatment, the clinical efficacy was evaluated, and the levels of serum creatinine, plasma albumin, and 24 h urine protein, and the adverse reaction in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 78.13% and 93.75%,respectively, and there were differences between two groups(P < 0.05). After treatment, the levels of serum creatinine, plasma albumin, and 24 h urine protein in two groups were significantly decreased, and there were differences in the same group(P < 0.05).After treatment, the levels of serum creatinine, plasma albumin, and 24 h urine protein in the treatment group were lower than those in the control group, and there were differences between two groups(P < 0.05). After treatment, the incidence of adverse reactions in the treatment group was 18.7%, which was significantly lower than 37.5% in the control group, with significant difference between two groups(P < 0.05). Conclusion Shenyan Kangfu Tablets combined with Cyclosporin Soft Capsules has significant efficacy in treatment of refractory nephrotic syndrome, can improve the renal function with less adverse reactions, which has a certain clinical application value.
引文
[1]林丽,钟飞,杨树升.原发性肾病综合征发生机制的研究进展[J].湖南中医学院学报,2003,23(1):62-64.
[2]简珊,何艳燕,宋红梅,等.环孢素A治疗儿童难治性肾病综合征疗效观察[J].临床儿科杂志,2010,28(4):330-333.
[3]赵亚清.肾炎康复片和雷公藤多甙片联合治疗难治性肾病综合征的疗效观察[J].中国中西医结合肾病杂志,2004,5(12):725-726.
[4]孙传兴.临床疾病诊断依据治愈好转标准[M].第2版.北京:人民军医出版社,2002:134.
[5]郝静,袁伟杰.难治性肾病综合征的病因及治疗研究进展[J].中国中西医结合肾病杂志,2013,14(6):553-555.
[6]朱玉娴,张玉强,孙丽君,等.环孢素A与吗替麦考酚酯治疗难治性肾病综合征疗效对比[J].中国中西医结合肾病杂志,2010,11(11):971-974.
[7]殷士涛,彭月萍.肾炎康复片联合坎地沙坦治疗原发性肾病综合征临床观察[J].北京中医药,2012,31(7):539-541.
[8]黄钟雄,詹鹏飞,肖俊锐.肾病综合征血液及尿微量蛋白相关性的研究[J].海南医学院学报,2013,19(7):944-946,950.
[9]樊春荔,吴嘉,卜晓敏,等.肾病综合征患儿的血清游离脂肪酸与白蛋白比值显著升高[J].南方医科大学学报,2016,36(10):1382-1385.
[10]邱杰山,沈水娟,刘琪,等.慢性肾脏病患者晨尿微量白蛋白/尿肌酐比值与24h尿蛋白定量的相关性分析[J].中国卫生检验杂志,2013,23(3):693-696.
[2]简珊,何艳燕,宋红梅,等.环孢素A治疗儿童难治性肾病综合征疗效观察[J].临床儿科杂志,2010,28(4):330-333.
[3]赵亚清.肾炎康复片和雷公藤多甙片联合治疗难治性肾病综合征的疗效观察[J].中国中西医结合肾病杂志,2004,5(12):725-726.
[4]孙传兴.临床疾病诊断依据治愈好转标准[M].第2版.北京:人民军医出版社,2002:134.
[5]郝静,袁伟杰.难治性肾病综合征的病因及治疗研究进展[J].中国中西医结合肾病杂志,2013,14(6):553-555.
[6]朱玉娴,张玉强,孙丽君,等.环孢素A与吗替麦考酚酯治疗难治性肾病综合征疗效对比[J].中国中西医结合肾病杂志,2010,11(11):971-974.
[7]殷士涛,彭月萍.肾炎康复片联合坎地沙坦治疗原发性肾病综合征临床观察[J].北京中医药,2012,31(7):539-541.
[8]黄钟雄,詹鹏飞,肖俊锐.肾病综合征血液及尿微量蛋白相关性的研究[J].海南医学院学报,2013,19(7):944-946,950.
[9]樊春荔,吴嘉,卜晓敏,等.肾病综合征患儿的血清游离脂肪酸与白蛋白比值显著升高[J].南方医科大学学报,2016,36(10):1382-1385.
[10]邱杰山,沈水娟,刘琪,等.慢性肾脏病患者晨尿微量白蛋白/尿肌酐比值与24h尿蛋白定量的相关性分析[J].中国卫生检验杂志,2013,23(3):693-696.